|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1995
|
|
gptkbp:approvedBy
|
gptkb:Switzerland
|
|
gptkbp:ATCCode
|
L04AA06
|
|
gptkbp:brand
|
gptkb:CellCept
Myfortic (related formulation)
|
|
gptkbp:CASNumber
|
128794-94-5
|
|
gptkbp:chemicalFormula
|
C23H31NO7
|
|
gptkbp:contraindication
|
pregnancy
hypersensitivity to mycophenolate mofetil
|
|
gptkbp:drugClass
|
immunosuppressant
|
|
gptkbp:eliminationHalfLife
|
16-18 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:tablet
capsule
intravenous infusion
oral suspension
|
|
gptkbp:genericName
|
gptkb:mycophenolate_mofetil
|
|
gptkbp:hasBoxedWarning
|
risk of infection and malignancy
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CellCept
|
|
gptkbp:indication
|
heart transplant rejection prevention
kidney transplant rejection prevention
liver transplant rejection prevention
|
|
gptkbp:interactsWith
|
gptkb:proton_pump_inhibitors
gptkb:rifampin
gptkb:acyclovir
live vaccines
antacids
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
inhibits inosine monophosphate dehydrogenase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2009 (US)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:pregnancyWarning
|
may cause birth defects
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:riskOfMalignancy
|
increased
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
leukopenia
increased risk of infection
|
|
gptkbp:storage
|
below 30°C
|
|
gptkbp:usedFor
|
prevention of organ transplant rejection
treatment of autoimmune diseases
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:F._Hoffmann-La_Roche_AG
|
|
gptkbp:bfsLayer
|
7
|